Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Haseki Training and Research Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06741930CT.gov Pro-Epileptic Effects of IV Ketamine | — | Completed | — | — | — |
NCT05346666CT.gov Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus. | — | Unknown | — | — | — |
NCT03513757CT.gov Dexmedetomidine and Propofol for Pediatric MRI Sedation | — | Completed | — | — | — |
NCT02633241CT.gov A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging | — | Completed | — | — | — |
NCT02645279CT.gov Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates | — | Unknown | — | — | — |
NCT02988050CT.gov Conscious Sedation for Epilepsy Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Propofol (this asset) | Haseki Training and Research Hospital | Approved | BB · 68 |
| Lamotrigine | Assiut University | P4 | BBB |
| Levetiracetam | Beijing Tiantan Hospital | P4 | BBB |
| Eslicarbazepine Acetate | Bial - Portela C S.A. | P4 | BBB |
| Topiramate | Université de Sherbrooke | P4 | BBB |
| Neurotop | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Lacosamide | Second Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Valproic Acid | Sanofi | P4 | BBB |
| Midazolam | Haseki Training and Research Hospital | P4 | BBB |
+42 more in the Epilepsy cohort
Other indications for Propofol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Headache Disorder | — | P4 | BBB · 73 |
| Morbid Obesity | — | P4 | BBB · 73 |
| Alzheimer Disease | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Propofol in Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/propofol-epilepsy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →